NTLA FY 2023 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M-30.4% YoY

Gross Profit

$27M75.3% margin

Operating Income

-$515M-1420.5% margin

Net Income

-$481M-1326.5% margin

EPS (Diluted)

$-5.42

Cash Flow

Operating Cash Flow

-$394M

Free Cash Flow

-$408M

Stock-Based Comp.

$134M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$251M

Stockholders' Equity

$1.1B

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$52M	-30.4%
Gross Profit	$27M	$45M	-38.7%
Operating Income	-$515M	-$458M	-12.5%
Net Income	-$481M	-$474M	-1.5%